Intelligent Nanocellulose-Based Oral Dosing Systems for Personalized Medicine

This invention envisions a next-generation oral dosing system that integrates nanocellulose-derived hydrogels with artificial intelligence-controlled release mechanisms, machine learning-assisted molecular simulations, and wearable devices for personalized medicine.

The original patent disclosed a versatile nanocellulose-derived hydrogel drug delivery system for extended release in oral dosing pharmaceuticals. However, the system lacked the ability to adapt to individual patient needs and did not leverage advancements in AI, machine learning, and wearable technologies. The new inventive concept addresses these limitations by introducing intelligent, personalized, and adaptive oral dosing systems.

The new system comprises a nanocellulose-derived hydrogel matrix infused with AI-controlled release mechanisms, which can be tailored to individual patient needs through machine learning-assisted molecular simulations. The system can be integrated with wearable devices, such as transdermal patches, to enable real-time monitoring and adaptive release of therapeutic agents. Additionally, the invention encompasses a biohybrid system combining living cells with nanocellulose-derived scaffolds for sustained release of therapeutic proteins and real-time monitoring of treatment efficacy.

The new claims introduce the concept of AI-controlled release mechanisms, machine learning-assisted molecular simulations, and wearable devices, which are not present in the original patent. These advancements enable personalized medicine and adaptive oral dosing systems, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include the use of different types of wearable devices, such as smartwatches or implantable sensors, or the integration of additional AI algorithms for predictive analytics and treatment optimization. Variations of the system could also be developed for specific disease indications or patient populations.

The intelligent nanocellulose-based oral dosing system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, chronic disease management, and precision health. The market for wearable devices and AI-powered healthcare solutions is rapidly growing, and this invention is well-positioned to capitalize on these trends.